Key Highlights
- Arecor Therapeutics (LSE:AREC) is a formulation-science company developing improved medicines, including its lead insulin candidate AT278.
- In September 2025 Arecor signed a co-development agreement with Sequel Med Tech to integrate AT278 into Sequel's twiist automated insulin delivery system.
- The company secured up to $11 million of non-dilutive Royalty financing from Ligand Pharmaceuticals.
- A pivotal Phase 2 trial for AT278 is a key upcoming catalyst for the company.
- Arecor faces a funding requirement looming in 2027, and its Investment case rests significantly on the outcome of the Phase 2 trial.
Arecor has spent a decade turning formulation science into better medicines. Non-dilutive funding, a marquee insulin-delivery Partnership and a pivotal Phase 2 trial now loom. With biotech financing thawing, could this £22m minnow reclaim investor attention?
Britain's small-cap biotech sector has endured a brutal few years of scarce Capital and battered valuations. Arecor Therapeutics (LSE:AREC), a Cambridge-based formulation-science company valued at around £22m, has felt that chill: its shares changed hands near 85p in August 2026, still lower over the past twelve months. Yet the picture beneath the price has shifted. Arecor has secured non-dilutive funding, signed a co-development deal with a US insulin-delivery specialist, and is preparing to move its lead ultra-concentrated insulin into a pivotal Phase 2 trial. With the wider biotech funding market showing tentative signs of revival, the question is whether these building blocks can put a long-overlooked stock back on investors' radar.
The Company
Arecor is built around a proprietary formulation technology it calls Arestat. In plain terms, Arestat is a toolkit of techniques for reformulating existing drugs, chiefly proteins and peptides, so they are more stable, more concentrated or easier to administer. That can turn a fridge-bound injection into a more robust product, or pack a higher dose into a smaller volume. The company applies the platform in two ways: developing its own proprietary medicines, largely in diabetes, and licensing the technology to pharmaceutical partners who pay development fees and, potentially, future royalties.
Its flagship is AT278, described as the only ultra-concentrated (500 units per millilitre), ultra-rapid-acting insulin in development. A higher-strength, faster-acting insulin could suit patients who need large doses and help enable smaller, wearable insulin pumps. A second candidate, AT247, is a rapid-acting insulin. Beyond diabetes, Arecor is developing oral formulations of peptide drugs, including GLP-1 receptor agonists, the class behind today's blockbuster weight-loss injections, with the aim of delivering them as pills rather than jabs.
Why the Stock Is in Focus
Several developments have re-energised the story. In September 2025 Arecor signed a co-development agreement with US firm Sequel Med Tech to integrate AT278 into Sequel's twiist automated insulin delivery system, with both sides later signalling intent to widen this into a full co-development and commercialisation partnership. Alongside it, Arecor secured up to $11m (roughly £8m) of non-dilutive royalty financing from Ligand Pharmaceuticals, $7m upfront and $4m tied to milestones, money raised without issuing new shares.
Crucially for a cash-hungry biotech, Arecor has also reported positive US Food and Drug Administration feedback on the Phase 2 design for AT278, with the trial anticipated to begin in the second half of 2026. For a company whose value hinges on clinical progress, a pivotal-stage insulin trial backed by a commercial partner is the kind of catalyst that can re-rate a micro-cap, or sink it if the data disappoint.
Financial Position
Arecor's full-year 2025 results, published on 13 April 2026, showed Revenue of £1.7m and Research and Development spending of £2.7m. Unusually for a development-stage biotech, the company reported an operating profit of £0.9m, against a £5.2m loss the year before. Investors should treat that figure cautiously: the swing largely reflects the wind-down of loss-making commercial operations, the Tetris Pharma distribution Business discontinued by 30 September 2025, rather than underlying profitability, and the core drug-development activity remains loss-making.
Cash and equivalents stood at £6.1m at year end, up from £3.2m, boosted by the Ligand financing. Management guided that current cash should fund operations until around May 2027, implying a need for further funding by the second quarter of that year. As with any micro-cap, precise figures should be checked against the company's own filings, and readers should note that the runway guidance is a management estimate dependent on spending assumptions.
Bull Case
The optimistic view is that Arecor has de-risked itself in ways the share price has yet to reward. Non-dilutive financing from Ligand extends the runway without punishing existing shareholders, a rare feat in a sector where cash calls have crushed valuations. The Sequel tie-up gives AT278 a credible route to market inside a next-generation insulin pump, and validation from a commercial partner matters.
If the Phase 2 trial confirms AT278's ultra-concentrated, ultra-rapid profile, Arecor would own a differentiated asset in a large diabetes market, with optionality from its oral-peptide work in the fast-growing GLP-1 space. Meanwhile the Arestat licensing business provides recurring partner revenue that most early-stage biotechs lack, offering a modest commercial floor beneath the clinical upside.
Bear Case and Risks
The cautious view is that Arecor is still a pre-profit biotech with a looming funding cliff. The May 2027 runway means another financing is likely within roughly a year, and if Capital Markets stay difficult, that could mean a dilutive raise at a depressed price or unfavourable terms. The apparent operating profit flatters a business that remains fundamentally loss-making at the research level.
Clinical risk is ever-present: Phase 2 trials can fail, throw up safety signals or slip, and insulin is a competitive, price-pressured market dominated by giants. The Sequel partnership's commercial terms and its expansion into a fuller deal are not guaranteed. Shares are thinly traded, and news flow can move the price sharply in either direction. Investors should also remember that a broader biotech funding revival, if it stalls, would remove a key plank of the bull thesis.
What Investors Should Watch Next
The single biggest catalyst is the start of the AT278 Phase 2 trial, guided for the second half of 2026, followed in time by its readout. Confirmation that the Sequel relationship has expanded into a full co-development and commercialisation partnership would be a significant milestone, as would any new licensing deals for the Arestat platform.
On financing, watch for how and when Arecor addresses the funding requirement flagged for the second quarter of 2027; the terms of any raise will matter greatly to existing holders. Interim results covering the first half of 2026 are typically published in September, and progress reports on the oral GLP-1 peptide programme are a further, longer-dated marker.
Outlook
Arecor is a genuinely interesting formulation-science business with a differentiated insulin asset, a validating industry partner and, unusually, a stream of licensing revenue. The headline premise has real substance: non-dilutive funding and marquee partnerships suggest the company is navigating the biotech capital drought better than many peers. But the premise only half holds. The shares remain depressed, a funding requirement looms in 2027, and the value proposition rests on a Phase 2 trial that has yet to start, let alone succeed. For risk-tolerant investors, Arecor offers a clearly defined set of catalysts over the next eighteen months. For the cautious, the combination of clinical risk and a funding cliff argues for watching the trial and the Balance Sheet closely before drawing conclusions.






Please wait processing your request...